Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 2-(4-(6-fluoropyridin-2-yl)benzyl)-5-methyl-3-(phenylamino)-5,6a,7,8,9,9a-hexahydrocyclopenta(4,5)imidazo(1,2-a)pyrazolo(4,3-e)pyrimidin-4-(2h)-one
2. Iti-214
1. Lenrispodun
2. 1160521-50-5
3. Iti-214
4. Iti-214 Free Base
5. Iti-214f
6. Lenrispodun [usan]
7. Iti-214 (free Base)
8. 3gbo34d1be
9. Ic200214
10. Chembl3769414
11. Ic-200214
12. (11r,15s)-5-anilino-4-[[4-(6-fluoropyridin-2-yl)phenyl]methyl]-8-methyl-1,3,4,8,10-pentazatetracyclo[7.6.0.02,6.011,15]pentadeca-2,5,9-trien-7-one
13. Iti214 (free Base)
14. (11r,15s)-4-{[4-(6-fluoropyridin-2-yl)phenyl]methyl}-8-methyl-5-(phenylamino)-1,3,4,8,10-pentaazatetracyclo[7.6.0.02,6.011,15]pentadeca-2,5,9-trien-7-one
15. Cyclopent(4,5)imidazo(1,2-a)pyrazolo(4,3-e)pyrimidin-4(2h)-one, 2-((4-(6-fluoro-2-pyridinyl)phenyl)methyl)-5,6a,7,8,9,9a-hexahydro-5-methyl-3-(phenylamino)-, (6ar,9as)-
16. Pde1-in-1
17. Lenrispodun [inn]
18. Unii-3gbo34d1be
19. Pde4 (r)-(-)-rolipram
20. Schembl10201342
21. Gtpl12003
22. Bcp16186
23. Bdbm50150119
24. Who 11635
25. Zinc142626599
26. Compound 3 [pmid: 26789933]
27. Cs-3621
28. Db15039
29. (6ar,9as)-5,6a,7,8,9,9a-hexahydro-5-methyl-3-(phenylamino)-2-((4-(6-fluoropyridin-2-yl)phenyl)methyl)-cyclopent[4,5]imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(2h)-one
30. (6ar,9as)-5,6a,7,8,9,9a-hexahydro-5-methyl-3-(phenylamino)-2-((4-(6-fluoropyridin-2-yl)phenyl)methyl)cyclopent[4,5]imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(2h)-one
31. Hy-12501
32. Iti-214 Free Base;iti 214 Free Base
33. J3.605.616i
34. A858329
35. Q27454893
36. (6ar,9as)-2-((4-(6-fluoro-2-pyridinyl)phenyl)methyl)-5,6a,7,8,9,9ahexahydro- 5-methyl-3-(phenylamino)cyclopent(4,5)imidazo(1,2-a)pyrazolo(4,3- E)pyrimidin-4(2h)-one
37. (6ar,9as)-5,6a,7,8,9,9a-hexahydro-5-methyl-3-(phenylamino)-2-((4-(6-fluoropyridin-2-yl)phenyl)methyl)-cyclopent[4,5]imidazo-[1,2-a]pyrazolo[4,3-e]pyrimidin-4(2h)-one
| Molecular Weight | 507.6 g/mol |
|---|---|
| Molecular Formula | C29H26FN7O |
| XLogP3 | 5.1 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 5 |
| Exact Mass | 507.21828664 g/mol |
| Monoisotopic Mass | 507.21828664 g/mol |
| Topological Polar Surface Area | 78.6 Ų |
| Heavy Atom Count | 38 |
| Formal Charge | 0 |
| Complexity | 903 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
ABOUT THIS PAGE
A ITI214 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of ITI214, including repackagers and relabelers. The FDA regulates ITI214 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. ITI214 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A ITI214 supplier is an individual or a company that provides ITI214 active pharmaceutical ingredient (API) or ITI214 finished formulations upon request. The ITI214 suppliers may include ITI214 API manufacturers, exporters, distributors and traders.
ITI214 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of ITI214 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right ITI214 GMP manufacturer or ITI214 GMP API supplier for your needs.
A ITI214 CoA (Certificate of Analysis) is a formal document that attests to ITI214's compliance with ITI214 specifications and serves as a tool for batch-level quality control.
ITI214 CoA mostly includes findings from lab analyses of a specific batch. For each ITI214 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
ITI214 may be tested according to a variety of international standards, such as European Pharmacopoeia (ITI214 EP), ITI214 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (ITI214 USP).
LOOKING FOR A SUPPLIER?
